| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Sangamo Therapeutics, Inc.$0.17
+0.02 (+10.33%)
D 39Pipeline Score Fair Value Biotech · Commercial
Market Cap
73.58 M
EPS
-0.44
P/E Ratio
-
Value Trade
559.66 K
SEC Financials
Q1 2026Dilution Risk
Revenue
1.44 M
R&D Expenses
26.57 M
Operating CF
-19.28 M
Total Assets
59.97 M
Total Liabilities
78.92 M
Equity
-18.95 M
D/E Ratio
12,345
-3.11 %
Week
-29.07 %
1 Month
-60.87 %
3 Month
-67.41 %
6 Month
-98.42 %
5 Year
-98.82 %
All Time
Cash Data
Cash Position
27.59 M
Monthly Burn
6.43 M
Runway
2.6 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
3.28 M
52 Week Range
0.12 - 0.77
% held by Insiders
2.15 %
% held by Institutions
15.14 %
Enterprise Value
79.42 M
Total Shares
336.39 M
Short %
7.64 %
Float Shares
324.28 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D39
Pipeline Score $66M
Pipeline ValueFair Value
Valuation Signal7
Drugs Scored0.9x
rNPV / MCap Top 55%
Micro Cap (rank 411 of 911)
Percentile RankSangamo Therapeutics, Inc. faces pipeline headwinds (39/100), with $6.4B risk-adjusted pipeline value, led by ZFN modified T cells in HIV (Phase 1), across $198B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZFN modified T cells Monoclonal antibody | HIV | Phase 1 | NCT00842634 | 43% | $2.6B | COMPLETED | 12 | - | - | Jan 1, 2013 | - | Feb 8, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
isaralgagene civaparvovec | Fabry disease | Phase 1/2 | 2026-02-04 | mean annualized e GFR slope: 1.965 mL/min/1.73m2/year; confidence interval: -0.153, 4.083; mean annualized e GFR slope 104 weeks: 1.747 mL/min/1.73m2/year; confidence interval 104 weeks: -0.106, 3.601 Read More | Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 Read More | |
isaralgagene civaparvovec | Fabry disease | Phase 1/2 | 2026-02-04 | mean annualized e GFR slope: 1.965 mL/min/1.73m2/year; confidence interval: -0.153, 4.083; mean annualized e GFR slope 104 weeks: 1.747 mL/min/1.73m2/year; confidence interval 104 weeks: -0.106, 3.601 Read More | Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 Read More | |
isaralgagene civaparvovec | Fabry disease | Phase 1/2 | 2026-02-04 | mean annualized e GFR slope: 1.965 mL/min/1.73m2/year; confidence interval: -0.153, 4.083; mean annualized e GFR slope 104 weeks: 1.747 mL/min/1.73m2/year; confidence interval 104 weeks: -0.106, 3.601 Read More | Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SGMO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SGMO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How SGMO ranks across every disease it competes inCompetitive Position is a premium feature
See how SGMO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial